The IASLC (International Association for the Study of Lung Cancer) 7th edition lung cancer staging system was proposed in 2010 and has now been updated and superseded by the 8th edition, published in 2016.
Small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) used to be staged di...
The IASLC (International Association for the Study of Lung Cancer) 8th edition lung cancer staging system was introduced in 2016 and supersedes the IASLC 7th edition.
T: primary tumour
Tx: primary tumour cannot be assessed or tumour proven by the presence of malignant cells in spu...
A number of staging systems have been described for staging of malignant pleural mesothelioma. Below is the International Mesothelioma Interest Group TNM staging system.
T - Tumour
Tx: primary tumour cannot be assessed
T0: no evidence of primary tumour
The Masaoka staging system is commonly adopted for thymomas 1-3, and is the most important determinant of survival following surgical resection 4:
stage I: intact thymic capsule
stage II: capsular invasion into adjacent mediastinal fat or pleura
stage III: macroscopic invasion into adjacent o...
Oesophageal cancer staging can depend slightly on whether the tumour is squamous cell or adenocarcinoma subtype. Due to the lack of a serosal layer, oesophageal cancer often tends to have mediastinal spread at the time of diagnosis.
Tx: primary tumour cannot be...
Siltzbach system is a chest radiographic staging method for sarcoidosis.
stage 0: normal chest radigraph: 10% at time of diagnosis
stage I: lymph node enlargement: 50% at time of diagnosis
stage II: lymph node enlargement and pulmonary opacities: 30% at time of diagnosis
stage III: pulmonary...
Previously, small cell lung cancer (SCLC) was not staged in the same manner as non-small cell lung cancer (NSCLC), but since 2013 both are staged using the IASLC (International Association for the Study of Lung Cancer) lung cancer staging system (currently in its 8th edition, published in 2016)....
Visceral pleural invasion is a feature that can be seen in lung cancers. It is defined as tumour extension beyond the elastic layer of the visceral pleura. It is considered an aggressive sign and one of the most important adverse prognostic factors in non-small cell lung cancers 1.